Azithromycin

C difficile risk
Medium
Oral Bioavailability
Moderate
Cost
IV:$ PO:$

Spectrum Of Activity

Dosing

250-500mg PO/IV Q24h

Respiratory Infection 500mg PO/IV on day 1 then 250mg daily for 4 days

General Information

  • Community acquired pneumonia

  • Pertussis

  • Upper respiratory tract infections

  • Chlamidial infections

  • Mycobacterial infections

  • Mycobacterium avium complex (MAC) prophylaxis in HIV patients

Monitor QTc in patients with increased risk

Prolongation of QTc interval. Association with increased cardiovascular mortality in observational studies.

Prolonged half life may contribute to macrolide resistance

  • Other drugs that prolong QTc

  • Increases cyclosporine levels

  • May increase digoxin levels

  • Statins increased risk of rhabdomyolysis

Very high tissue penetration and concentration intracellularly means in vivo activity may not be predicted by in vitro testing - e.g. Salmonella species.

Antimicrobial class: Macrolide

Pregnancy category: B

Average serum half life: 68 hours

Biliary penetration: Therapeutic

CSF penetration: Poor

Lung penetration: Therapeutic

Urine penetration: Poor